Mather Group
RXRX icon

Mather Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Mather Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1,030
Closed -$3.78K – 2304
2026
Q2 		$3.78K Sell
1,030
-1,250
-55% -$4.16K ﹤0.01% 1664
2026
Q1 		$7K Buy
+2,280
New +$8.81K ﹤0.01% 1526
2025
Q4 		– Sell
-1,030
Closed -$5.03K – 1454
2025
Q3 		$5.03K Buy
+1,030
New +$5.41K ﹤0.01% 1393

Other funds holding RXRX

Green Alpha Advisors
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Sowell Financial Services
Sowell Financial Services North Little Rock, Arkansas $3.61B AUM 22.22% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Cherry Creek Investment Advisors
Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return
Whalen Wealth Management
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
Kieckhefer Group
Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return
Prime Capital Investment Advisors
Prime Capital Investment Advisors Overland Park, Kansas $10.2B AUM 17.74% 1-Year Est. Return
Axxcess Wealth Management
Axxcess Wealth Management Carlsbad, California $2.44B AUM 16.42% 1-Year Est. Return
Accel Wealth Management
Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return

Mather Group's RXRX Position: Q3 2026 in Review

Mather Group sold out of Recursion Pharmaceuticals (RXRX) in Q3 2026, closing a stake of 1,030 shares — an estimated $3.78K sold.

Mather Group first reported a position in RXRX in Q3 2025 and held it in 3 quarters. The position peaked at $7K in Q1 2026. 41 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Mather Group reported no remaining Recursion Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Mather Group sold 1,030 Recursion Pharmaceuticals shares in Q3 2026, an estimated $3.78K.
  • Mather Group first reported a position in Recursion Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Mather Group's Recursion Pharmaceuticals position peaked at $7K in Q1 2026.
  • 41 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.